GreenLight SPAC Presentation Deck

Anticipated use of proceeds $282M (Estimated Cash in Trust and PIPE Proceeds) Human Health Plant Health Platform & Corporate Development Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. • Advance COVID-19 and seasonal flu vaccine candidates through clinical trials • Continue R&D efforts on further therapeutics • Launch pipeline of pest-protection products and first animal health product into market • Expand into other biological molecules (microbials, peptides, etc.) and applications • Build mRNA GMP manufacturing facility • Scale R&D processes, manufacturing capacity, and capabilities Buy versus make opportunities to accelerate growth and expand product/IP portfolio • Public company G&A costs ● 42

View entire presentation